Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $207.00 CLP
Change Today 0.00 / 0.00%
Volume 20.0
CFR On Other Exchanges
Sant. Comerc
As of 4:30 PM 04/30/15 All times are local (Market data is delayed by at least 15 minutes).

cfr pharmaceuticals sa (CFR) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/30/14 - $215.00
52 Week Low
05/5/14 - $115.32
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CFR PHARMACEUTICALS SA (CFR)

Related News

No related news articles were found.

cfr pharmaceuticals sa (CFR) Related Businessweek News

No Related Businessweek News Found

cfr pharmaceuticals sa (CFR) Details

CFR Pharmaceuticals S.A., a pharmaceutical company, engages in the research, development, manufacture, and commercialization of specialty branded generics and complex injectables. Its portfolio comprises products for the treatment of approximately 200 diseases and for general health care. The company offers specialty pharma products comprising women’s health, neurology, psychiatry, general medicine, pneumology, otorhinolaryngology, allergies, cardiology, dermatology, ophthalmology, and generic products. It also provides complex therapeutic drugs for the treatment of complex illnesses consisting sterile injectable products and lyophilized forms for anesthesia, infections, cardiology, and intensive care; and biological products, monoclonal antibodies, and treatments for dialysis, transplants, oncology, and rheumatology. In addition, the company offers over-the-counter products, nutrition products, food supplements, and homeopathic products. It operates in approximately 18 countries in the Americas, Europe, and Asia. The company was founded in 1922 and is based in Providencia, Chile. CFR Pharmaceuticals S.A. is a subsidiary of Talpiot Investments SpA.

Founded in 1922

cfr pharmaceuticals sa (CFR) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

cfr pharmaceuticals sa (CFR) Key Developments

CFR Pharmaceuticals (Chile) Announces Earnings Results for the Year 2014

CFR Pharmaceuticals (Chile) announced earnings results for the year 2014. The company has reported a 4.4% year on year revenue drop during 2014 with USD 86 million in losses from profits of USD 458 million in 2013. CFR's sales in Colombia have increased, but there was a decrease in Chile and Argentina tied to the exchange rates. According to the source, the company's negative performance could be blamed on the expenditures tied to the purchase of CFR shares by Abbott (US) and the loss incurred by the divestiture of the Unam subsidiary.

CFR Pharmaceuticals S.A.(SNSE:CFR) dropped from Chile IPSA Index

CFR Pharmaceuticals S.A. will be removed from Chile IPSA Index.

CFR Pharmaceuticals Reports Consolidated Earnings Results for the Second Quarter and First Half ended June 30, 2014

CFR Pharmaceuticals reported consolidated earnings results for the second quarter and first half ended June 30, 2014. For the quarter, the company reported revenues of USD 190.10 million against USD 206.8 million a year ago. EBITDA was USD 40.6 million against USD 50.6 million a year ago. Profit attributable to owners of parent was USD 20.2 million against USD 32.0 million a year ago. EBIT was USD 35.0 million against USD 44.5 million a year ago. During the second quarter of 2014, a more challenging environment, with the USD continuing with its trend of appreciation against local currencies, has put a significant amount of pressure in the industry margins of the emerging markets, and CFR has seen some of this pressure in margins during this period. However, the company is prepared to face this challenge, and, removing the FX effect, we can see that the underlying business is having a healthy grow, which is reflected in a 12.3% quarterly growth in constant currency. For the first half, the company reported revenues of USD 371.6 million against USD 374.0 million a year ago. EBITDA was USD 76.5 million against USD 89.6 million a year ago. Profit attributable to owners of parent was USD 50.0 million against USD 51.6 million a year ago. EBIT was USD 65.6 million against USD 77.5 million a year ago. Net cash flow from operating activities was USD 30.7 million against USD 38.3 million a year ago. Addition of PP&E was USD 6.3 million against USD 5.5 million a year ago. Addition of intangible assets was USD 3.9 million against USD 4.8 million a year ago. During the first half of 2014, CFR has been able to increase revenues and market share in the three markets they have in the Latam Golden West Coast ­Colombia, Chile and Peru­, even while those markets contracted in this period. The company’s strategy, which allowed to increase revenues by 17.8% in constant currency, also put in a unique position to compete in this environment, so the company remains optimistic about the future, aiming at generating double-digit revenue growth and leverage over fixed costs. Profit before taxes was USD 60.0 million compared to USD 61.0 million a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CFR:CI $207.00 CLP 0.00

CFR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CFR.
View Industry Companies

Industry Analysis


Industry Average

Valuation CFR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.8x
Price/Book 8.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CFR PHARMACEUTICALS SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at